Method Description Describes how the test is performed and provides a method-specific reference
Testing is performed on a Roche Cobas. The Roche Progesterone II assay is a competitive assay using electrochemiluminescence detection. Patient specimen, biotinylated monoclonal progesterone-specific antibody, and a progesterone derivative labeled with ruthenium complex are incubated with Danazol to release progesterone. Progesterone from the sample competes with the labeled progesterone derivative for the antibody binding site. After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin. The amount of the labeled progesterone derivative bound to the solid phase is inversely proportional to the progesterone content of the sample. This reaction mixture is aspirated into measuring cell where the bound microparticles are captured onto the electrode surface and unbound substances are removed. Voltage is applied to the electrode inducing a chemiluminescent emission, which is then measured against a calibration curve to determine the amount of progesterone in the patient specimen.(Package insert: Roche Cobas. Roche Diagnostics, Indianapolis, IN 09/2007)
PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Sunday; Continuously